Daiichi Sankyo and Merck dose first subject in ovarian cancer trial

Daiichi Sankyo and Merck dose first subject in ovarian cancer trial

Submitted by admin on April 4, 2024 - 10:53am
Source: 
Clinical Trials Arena
News Tags: 
Daiichi Sankyo
Merck
ovarian cancer
clinical trials
raludotatug deruxtecan
R-DXd
Headline: 
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
snippet: 

Daiichi Sankyo and Merck (MSD) have dosed the first subject in the global Phase II/III REJOICE-Ovarian01 clinical trial of raludotatug deruxtecan (R-DXd) in platinum-resistant, ovarian cancer patients.

Do Not Allow Advertisers to Use My Personal information